ArticleAtherosclerosis2011
In vivo knockdown of nicotinic acetylcholine receptor α1 diminishes aortic atherosclerosis.
Article in Atherosclerosis, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- Expression Profiles of α1nAChR, ERK1/2, c-FOS and Matrix Metalloproteinases Among Male Smokers with Acute Coronary Syndrome.International journal of molecular sciences · 2026Article
- Hydrodynamic Delivery: Characteristics, Applications, and Technological Advances.Pharmaceutics · 2023Review
- Myorelaxants in ARDS patients.Intensive care medicine · 2020Review
- Role of the α7 Nicotinic Acetylcholine Receptor in the Pathophysiology of Atherosclerosis.Frontiers in physiology · 2020Review
- Article
- Article
- Review
- Role of the nicotinic acetylcholine receptor α3 subtype in vascular inflammation.British journal of pharmacology · 2016Article
- Cell-type deconvolution with immune pathways identifies gene networks of host defense and immunopathology in leprosy.JCI insight · 2016Article
- Image-Guided Hydrodynamic Gene Delivery: Current Status and Future Directions.Pharmaceutics · 2015Review
- Association study of nicotinic acetylcholine receptor genes identifies a novel lung cancer susceptibility locus near CHRNA1 in African-Americans.Oncotarget · 2012Article
- Pathogenesis of abdominal aortic aneurysms: role of nicotine and nicotinic acetylcholine receptors.Mediators of inflammation · 2012Review
- New Insights Into Tobacco-Induced Vascular Disease: Clinical Ramifications.Methodist DeBakey cardiovascular journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveNicotinic acetylcholine receptor α1 (nAChRα1) was recently identified as a functional cell receptor for urokinase, a potent atherogenic molecule. Here, we test the hypothesis that nAChRα1 plays a role in the pathogenesis of atherosclerosis.
methodsApolipoprotein E-deficient mice were initially fed a Western diet for 8 wks. Plasmid DNA encoding scramble RNA (pscr) or siRNA (psir2) for nAChRα1 was injected into the mice (n=16) using an aortic hydrodynamic gene transfer protocol. Four mice from each group were sacrificed 7 days after the DNA injection to confirm the nAChRα1 gene silencing. The remaining mice continued on a Western diet for an additional 16 wks.
resultsThe nAChRα1 was up-regulated in aortic atherosclerotic lesions. A 78% knockdown of the nAChRα1 gene resulted in remarkably less severe aortic plaque growth and neovascularization at 16 wks (both P<0.05). In addition, significantly fewer macrophages (60% less) and myofibroblasts (80% less) presented in the atherosclerotic lesion of the psir2-treated mice. The protective mechanisms of the nAChRα1 knockdown may involve up-regulating interferon-γ/Y box protein-1 activity and down-regulating transforming growth factor-β expression.
conclusionsThe nAChRα1 gene plays a significant role at the artery wall, and reducing its expression decreases aortic plaque development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.